Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
Real-time Estimate Tradegate  -  02:32:58 2023-02-08 am EST
183.85 EUR   +0.66%
02/07EU considers ban on 'forever chemicals', urges search for alternatives
RE
02/07MERCK KGAA : Goldman Sachs gives a Sell rating
MD
02/06Afr : Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
EQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Xetra
02/01/2023 02/02/2023 02/03/2023 02/06/2023 02/07/2023 Date
182.5(c) 184.05(c) 185.9(c) 184.3(c) 182.65(c) Last
644 977 471 010 350 838 208 592 273 960 Volume
-4.48% +0.85% +1.01% -0.86% -0.90% Change
More quotes
Estimated financial data (e)
Sales 2022 22 263 M 23 811 M 23 811 M
Net income 2022 3 681 M 3 937 M 3 937 M
Net Debt 2022 7 082 M 7 574 M 7 574 M
P/E ratio 2022 21,6x
Yield 2022 1,11%
Sales 2023 22 927 M 24 521 M 24 521 M
Net income 2023 3 746 M 4 007 M 4 007 M
Net Debt 2023 5 055 M 5 407 M 5 407 M
P/E ratio 2023 21,2x
Yield 2023 1,15%
Capitalization 79 412 M 84 933 M 84 933 M
EV / Sales 2022 3,89x
EV / Sales 2023 3,68x
Nbr of Employees 63 723
Free-Float 29,7%
More Financials
Company
Merck KGaA is one of the world's leading pharmaceutical and chemical groups. Net sales break down by family of products as follows: - solutions and products for scientific and biotechnological research (45.7%); - pharmaceutical products (36%): prescription drugs for the treatment of diabetes, cancer, multiple sclerosis, infertility, cardiovascular disease, central nervous system disorders, inflammatory disorders,... 
Read more
Sector
Pharmaceuticals
Calendar
03/02 | 01:00amEarnings Release
More about the company
Ratings of Merck KGaA
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A
More Ratings
All news about MERCK KGAA
02/07EU considers ban on 'forever chemicals', urges search for alternatives
RE
02/07MERCK KGAA : Goldman Sachs gives a Sell rating
MD
02/06Afr : Merck KGaA: Preliminary announcement of the publication of quarterly reports and qua..
EQ
02/02MERCK KGAA : Downgraded from Buy to Sell by DZ Bank
MD
02/02MERCK KGAA : Credit Suisse reaffirms its Buy rating
MD
02/02European Midday Briefing: Stocks Buoyed by Fed's Tightening Slo..
DJ
02/01MERCK KGAA : Credit Suisse reiterates its Buy rating
MD
01/31MERCK KGAA : JP Morgan reiterates its Buy rating
MD
01/25MERCK KGAA : Buy rating from Barclays
MD
01/19Merck KGaA CEO on Retaining Talent
MT
01/16IG BCE wants drug reserve and 'perspective meeting' with Scholz
DP
01/11Transcript : MERCK Kommanditgesellschaft auf Aktien Presents at 41st Annual J..
CI
01/09MERCK KGAA : UBS remains its Buy rating
MD
01/06MERCK KGAA : Jefferies reiterates its Buy rating
MD
01/06Morgan Stanley raises Merck KGaA to 'Overweight' - Target 230 euros
DP
More news
News in other languages on MERCK KGAA
02/07L'Union européenne étudie une interdiction des substances chimiques PFAS
02/07L'UE étudie une interdiction des substances chimiques PFAS
02/07La UE estudia prohibir las "sustancias químicas permanentes" e insta a buscar alternati..
02/06Afr : Merck KGaA: Vorabbekanntmachung über die Veröffentlichung von Quartalsberichten und ..
02/06Afr : Merck KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß ..
More news
Analyst Recommendations on MERCK KGAA
More recommendations
Stock Trading Strategies
MERCK KGAA - 01/13
Technically solid
BUY
More Stock Trading Analysis
ETFs positioned on MERCK KGAAETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Deka MSCI Germany Climate Change ESG - EUR4.74%1.69%-NC
First Trust Germany AlphaDEX - EUR3.32%0.76%Germany
Deka DAX ex Financials 30 - EUR3.1%2.73%Germany
Lyxor 1 DAX 50 ESG (DR) (I) - EUR2.6%1.67%-Germany
IShares DAX ESG (DE) - EUR2.6%1.25%-NC
More ETFs positioned on MERCK KGAA
Analysis
Merck picks Goldman Sachs to launch pigments sale in 2023 - sources
Stock Pick
 MERCK KGAA
A European big pharma with positive momentum
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 182,65 €
Average target price 207,85 €
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Belén Garijo López Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Laura Matz Chief Science & Technology Officer
Danny Bar-Zohar Head-Development & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
MERCK KGAA0.97%84 933
KYOWA KIRIN CO. LTD.-4.64%11 665
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD-0.45%5 644
SK BIOPHARMACEUTICALS CO., LTD.0.14%4 434
BETTA PHARMACEUTICALS CO., LTD.27.56%3 885
INDIVIOR PLC4.75%3 184